Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
PREZCOBIX™ (darunavir/cobicistat) approved in the U.S. for the treatment of adults living with HIV-1

Combined fixed-dose tablet of darunavir and cobicistat can help reduce number of pills in a combination antiretroviral treatment regimen.

Published
30 January 2015
From
Janssen press release
U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults

Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences, Inc.

Published
30 January 2015
From
Bristol-Myers Squibb press release
Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

On 22 January 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dutrebis, 150 mg lamivudine/300 mg raltegravir, film-coated tablet intended for the treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children.

Published
26 January 2015
From
Street Insider
Exploring possible treatment options after virological failure with raltegravir

In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

Published
21 January 2015
From
CATIE
New anti HIV drug dolutegravir is effective at low doses

The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.

Published
21 January 2015
From
MMD Newswire
Hepatitis C drug delayed by NHS due to high cost

The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.

Published
16 January 2015
From
The Guardian
Janssen launches HIV combo Rezolsta in UK

Johnson & Johnson unit Janssen has launched its once-daily, fixed-dose HIV combination therapy Rezolsta in the UK.

 Rezolsta combines the company’s big-selling HIV therapy Prezista (darunavir) and Gilead Science’s Tybost (cobicistat).

Published
15 January 2015
From
Pharma Times
Argos tanks as its HIV immunotherapy flunks Phase II

The treatment, AGS-004, is a personalized immunotherapy designed to train patients' T cells to better attack HIV. In a placebo-controlled Phase IIb trial, AGS-004 missed its primary endpoint of significantly lowering viral load among chronically infected patients.

Published
12 January 2015
From
FierceBiotech
Gilead, Janssen Expand HIV Combo Collaborations

Janssen R&D Ireland and Gilead Sciences have expanded two existing HIV drug collaborations through agreements to develop new once-daily HIV tablets, the companies said today in separate announcements. The value of both collaborations was not disclosed.

Published
30 December 2014
From
Genetic Engineering & Biotechnology News
Gilead Sciences, Inc. Can't Do It Alone

On Monday, Gilead Sciences announced an expanded agreement with Johnson & Johnson to develop two different of cocktail pills to treat HIV. One drug will combine Gilead's tenofovir alafenamide, commonly called TAF, and Emtriva with Johnson & Johnson's Edurant. The other combines Gilead's TAF, Emtriva, and Tybost, along with Janssen's Prezista.

Published
30 December 2014
From
Motley Fool
← First12345...80Next →

Filter by country